Myomo(MYO) - 2023 Q2 - Quarterly Report

Revenue Growth - Total revenue for the three months ended June 30, 2023, increased by 62% to $5,958,544 compared to $3,677,575 in the same period of 2022, driven by a final license payment from a joint venture partner in China [107]. - Product revenue rose by 15% to $4,243,624 for the three months ended June 30, 2023, compared to $3,677,575 in the same period of 2022, attributed to a higher number of revenue units [107]. Gross Margin and Expenses - Gross margin improved to 71.8% for the three months ended June 30, 2023, up from 65.3% in the same period of 2022, due to the receipt of a final license payment recorded at 100% margin [109]. - Research and development expenses decreased by 11% to $564,235 for the three months ended June 30, 2023, compared to $632,872 in the same period of 2022 [113]. - Selling, general, and administrative expenses were $4,819,827 for the three months ended June 30, 2023, a slight increase of 3% compared to $4,664,088 in the same period of 2022 [111]. - Selling, general and administrative expenses (SG&A) increased by approximately $156,000, or 3%, during the three months ended June 30, 2023, compared to the same period in 2022 [116]. Cash Flow and Financing - Cash and cash equivalents increased to $6,006,283 as of June 30, 2023, compared to $5,345,967 as of December 31, 2022 [124]. - The company used approximately $2.1 million in cash for operating activities during the six months ended June 30, 2023, compared to $4.97 million in the same period in 2022 [133]. - The company generated $5.76 million in cash from financing activities during the six months ended June 30, 2023, primarily from a public equity offering [136]. Joint Ventures and Commitments - The company has a minimum 19.9% stake in a joint venture with Ryzur Medical, which has committed to invest between $8 million and $20 million over five years [98]. - The joint venture is expected to generate a minimum purchase commitment of $10.75 million in MyoPro Control System units over the next ten years, subject to regulatory approvals [99]. Regulatory Changes and Claims - The Centers for Medicare and Medicaid Services (CMS) proposed a rule that could change reimbursement for MyoPro sales to a lump sum basis, potentially improving cash flow [101]. - The company began submitting claims to CMS's billing contractors in March 2023, with six claims currently under review [102]. - The proposed rule by CMS on June 29, 2023, could change the reimbursement approach for MyoPro, potentially allowing for faster revenue recognition [127]. Operational Changes - The company undertook cost reduction activities, including a workforce reduction of approximately 12% in January 2023, expected to reduce operating expenses by approximately $2.0 million in 2023 [126]. Financial Performance - Interest income decreased significantly to $(103,439) for the three months ended June 30, 2023, from $(13,845) in the same period of 2022, a change of $(89,594) or N/M [118]. - Adjusted EBITDA for the three months ended June 30, 2023, was $(776,587), an improvement from $(2,501,756) in the same period in 2022 [123]. - The company has a working capital of approximately $8.3 million and stockholders' equity of approximately $8.8 million as of June 30, 2023 [124]. - The company has remaining capacity under its Purchase Agreement with Keystone of approximately 1.0 million shares as of June 30, 2023 [130]. Future Developments - The company expects to enhance existing products and increase R&D costs annually, focusing on the development of a pediatric version of the MyoPro, the MyoPal [112].